4. Financial assets
Securities
Securities comprise the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company |
|
Number 31.12.2020 |
|
Change |
|
Number 31.03.2021 |
|
Market price in original currency 31.03.2021 |
|
Valuation CHF mn 31.03.2021 |
|
Valuation CHF mn 31.12.2020 |
||
|
Ionis Pharmaceuticals |
|
8 220 000 |
|
(53 038) |
|
8 166 962 |
|
USD |
|
44.96 |
|
346.5 |
|
411.4 |
|
Moderna |
|
2 854 963 |
|
(154 963) |
|
2 700 000 |
|
USD |
|
130.95 |
|
333.6 |
|
264.0 |
|
Neurocrine Biosciences |
|
3 035 000 |
|
(119 600) |
|
2 915 400 |
|
USD |
|
97.25 |
|
267.5 |
|
257.5 |
|
Argenx SE |
|
921 332 |
|
9 206 |
|
930 538 |
|
USD |
|
275.39 |
|
241.8 |
|
239.8 |
|
Incyte |
|
2 900 000 |
|
(3 000) |
|
2 897 000 |
|
USD |
|
81.27 |
|
222.2 |
|
223.3 |
|
Agios Pharmaceuticals |
|
4 158 902 |
|
336 090 |
|
4 494 992 |
|
USD |
|
51.64 |
|
219.0 |
|
159.5 |
|
Alexion Pharmaceuticals |
|
1 294 428 |
|
– |
|
1 294 428 |
|
USD |
|
152.91 |
|
186.8 |
|
179.0 |
|
Vertex Pharmaceuticals |
|
900 000 |
|
– |
|
900 000 |
|
USD |
|
214.89 |
|
182.5 |
|
188.3 |
|
Fate Therapeutics |
|
2 030 000 |
|
131 336 |
|
2 161 336 |
|
USD |
|
82.45 |
|
168.2 |
|
163.4 |
|
Macrogenics |
|
4 815 564 |
|
255 000 |
|
5 070 564 |
|
USD |
|
31.85 |
|
152.4 |
|
97.4 |
|
Alnylam Pharmaceuticals |
|
1 155 000 |
|
(25 000) |
|
1 130 000 |
|
USD |
|
141.19 |
|
150.5 |
|
132.9 |
|
Radius Health |
|
7 455 714 |
|
– |
|
7 455 714 |
|
USD |
|
20.86 |
|
146.8 |
|
117.9 |
|
Biogen |
|
537 000 |
|
– |
|
537 000 |
|
USD |
|
279.75 |
|
141.8 |
|
116.4 |
|
Arvinas |
|
2 176 903 |
|
(120 000) |
|
2 056 903 |
|
USD |
|
66.10 |
|
128.3 |
|
163.7 |
|
Sage Therapeutics |
|
1 540 104 |
|
235 000 |
|
1 775 104 |
|
USD |
|
74.85 |
|
125.4 |
|
117.9 |
|
Halozyme Therapeutics |
|
3 970 000 |
|
(1 033 034) |
|
2 936 966 |
|
USD |
|
41.69 |
|
115.5 |
|
150.1 |
|
Intra-Cellular Therapies |
|
3 538 419 |
|
– |
|
3 538 419 |
|
USD |
|
33.93 |
|
113.3 |
|
99.6 |
|
Crispr Therapeutics |
|
900 884 |
|
68 700 |
|
969 584 |
|
USD |
|
121.85 |
|
111.5 |
|
122.1 |
|
Esperion Therapeutics |
|
3 947 964 |
|
– |
|
3 947 964 |
|
USD |
|
28.05 |
|
104.5 |
|
90.9 |
|
Scholar Rock Holding |
|
2 255 651 |
|
(155 526) |
|
2 100 125 |
|
USD |
|
50.66 |
|
100.4 |
|
96.9 |
|
Myovant Sciences |
|
4 757 039 |
|
390 000 |
|
5 147 039 |
|
USD |
|
20.58 |
|
100.0 |
|
116.3 |
|
Molecular Templates |
|
6 380 331 |
|
1 735 774 |
|
8 116 105 |
|
USD |
|
12.62 |
|
96.6 |
|
53.0 |
|
Generation Bio Co. |
|
2 333 180 |
|
60 000 |
|
2 393 180 |
|
USD |
|
28.46 |
|
64.3 |
|
58.6 |
|
Relay Therapeutics |
|
1 409 357 |
|
521 987 |
|
1 931 344 |
|
USD |
|
34.57 |
|
63.0 |
|
51.8 |
|
Exelixis |
|
2 835 000 |
|
– |
|
2 835 000 |
|
USD |
|
22.59 |
|
60.4 |
|
50.4 |
|
Black Diamond Therapeutics |
|
1 390 000 |
|
840 000 |
|
2 230 000 |
|
USD |
|
24.26 |
|
51.0 |
|
39.4 |
|
Essa Pharma |
|
– |
|
1 825 814 |
|
1 825 814 |
|
USD |
|
29.05 |
|
50.0 |
|
– |
|
Nektar Therapeutics |
|
2 620 676 |
|
– |
|
2 620 676 |
|
USD |
|
20.00 |
|
49.5 |
|
39.4 |
|
Revolution Medicines |
|
– |
|
1 007 770 |
|
1 007 770 |
|
USD |
|
45.88 |
|
43.6 |
|
– |
|
Beam Therapeutics |
|
396 821 |
|
170 000 |
|
566 821 |
|
USD |
|
80.04 |
|
42.8 |
|
28.7 |
|
Mersana Therapeutics |
|
1 885 000 |
|
875 000 |
|
2 760 000 |
|
USD |
|
16.18 |
|
42.1 |
|
44.4 |
|
Kezar Life Sciences |
|
4 533 148 |
|
– |
|
4 533 148 |
|
USD |
|
5.96 |
|
25.5 |
|
20.9 |
|
Homology Medicines |
|
1 737 122 |
|
– |
|
1 737 122 |
|
USD |
|
9.41 |
|
15.4 |
|
17.4 |
|
Wave Life Sciences |
|
2 602 858 |
|
– |
|
2 602 858 |
|
USD |
|
5.61 |
|
13.8 |
|
18.1 |
|
Voyager Therapeutics |
|
2 680 283 |
|
(2 680 283) |
|
– |
|
USD |
|
n.a |
|
– |
|
17.0 |
|
Cidara Therapeutics |
|
2 822 495 |
|
(2 822 495) |
|
– |
|
USD |
|
n.a |
|
– |
|
5.0 |
|
Total shares |
|
|
|
|
|
|
|
|
|
|
|
4 276.5 |
|
3 952.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alder Biopharmaceuticals – Contingent Value Right |
|
2 766 008 |
|
– |
|
2 766 008 |
|
USD |
|
0.88 |
|
2.3 |
|
2.2 |
|
Bristol-Myers Squibb – Contingent Value Right |
|
800 000 |
|
(800 000) |
|
– |
|
USD |
|
n.a |
|
– |
|
– |
|
Total derivative instruments |
|
|
|
|
|
|
|
|
|
|
|
2.3 |
|
2.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
|
|
4 278.8 |
|
3 954.7 |
The changes in value of securities at fair value through profit or loss by investment category are as follows (in CHF 1 000):
|
|
|
Listed shares |
|
Unlisted shares |
|
Derivative instruments |
|
Total |
|
Opening balance as at 01.01.2020 at fair values |
|
3 518 985 |
|
– |
|
4 685 |
|
3 523 670 |
|
Purchases |
|
699 570 |
|
– |
|
– |
|
699 570 |
|
Sales |
|
(1 010 092) |
|
– |
|
– |
|
(1 010 092) |
|
Net gains/(losses) from securities |
|
744 042 |
|
– |
|
(2 531) |
|
741 511 |
|
Realized gains |
|
364 618 |
|
– |
|
– |
|
364 618 |
|
Realized losses |
|
(83 963) |
|
– |
|
– |
|
(83 963) |
|
Unrealized gains |
|
882 536 |
|
– |
|
– |
|
882 536 |
|
Unrealized losses |
|
(419 149) |
|
– |
|
(2 531) |
|
(421 680) |
|
Closing balance as at 31.12.2020 at fair values |
|
3 952 504 |
|
– |
|
2 155 |
|
3 954 659 |
|
|
|
|
|
|
|
|
|
|
|
Opening balance as at 01.01.2021 at fair values |
|
3 952 504 |
|
– |
|
2 155 |
|
3 954 659 |
|
Purchases |
|
286 441 |
|
– |
|
– |
|
286 441 |
|
Sales |
|
(197 887) |
|
– |
|
– |
|
(197 887) |
|
Net gains/(losses) from securities |
|
235 413 |
|
– |
|
142 |
|
235 555 |
|
Realized gains |
|
32 920 |
|
– |
|
– |
|
32 920 |
|
Realized losses |
|
(1 530) |
|
– |
|
(2 330) |
|
(3 860) |
|
Unrealized gains |
|
388 672 |
|
– |
|
142 |
|
388 814 |
|
Unrealized losses |
|
(184 649) |
|
– |
|
2 330 |
|
(182 319) |
|
Closing balance as at 31.03.2021 at fair values |
|
4 276 471 |
|
– |
|
2 297 |
|
4 278 768 |